Kenko Imalytics is a platform of MRI-based clinical devices that transform multiparametric MRI into quantitative, explainable imaging biomarkers. These devices provide clinically interpretable insight into tumour behaviour, supporting radiologists and clinical teams in making clearer, more consistent decisions across the oncology pathway.
MRI is the most powerful tool for understanding tumour behaviour, yet it remains underused because interpretation is complex and time, consuming. What used to take hours can now be done in minutes.
Kenko Imalytics moves beyond qualitative MRI interpretation and probability-based outputs by transforming multiparametric MRI into quantitative, explainable imaging biomarkers. By analysing perfusion, diffusion, and anatomical context together, it provides clinically interpretable insight into tumour behaviour, supporting clearer and more consistent decisions across the oncology pathway.
Kenko Breast AI+ transforms multiparametric breast MRI into quantitative, explainable imaging biomarkers that are clear, visual, and clinically interpretable. By reducing reading time, lowering false positives and false negatives, and providing objective insight into tumour behaviour, it supports faster interpretation and strengthens confidence in clinical decisions and tumour boards.
Kenko Imalytics includes devices for breast and prostate MRI, with additional devices for rectum, liver, and bladder currently under development. Each is built on the same approach: transforming multiparametric MRI into quantitative, explainable imaging biomarkers that provide clinically interpretable insight into tumour behaviour.
Kenko Imalytics’ devises interpret tumour behaviour using complementary MRI biomarkers derived from perfusion, diffusion, and anatomical context. By analysing vascular dynamics, tissue cellularity, and structural information together, it provides quantitative insight into lesion characterisation, tumour heterogeneity, and biological behaviour, supporting clearer, more consistent clinical decisions.
Kenko Imalytics supports radiologists by transforming multiparametric MRI into quantitative, explainable imaging biomarkers. It enables clearer lesion characterisation and more consistent interpretation while maintaining full clinical control over decision-making and reporting.
Kenko Imalytics’ devises interpret tumour behaviour using complementary MRI biomarkers derived from perfusion, diffusion, and anatomical context. By analysing vascular dynamics, tissue cellularity, and structural information together, it provides quantitative insight into lesion characterisation, tumour heterogeneity, and biological behaviour, supporting clearer, more consistent clinical decisions.
Kenko Imalytics supports radiologists by transforming multiparametric MRI into quantitative, explainable imaging biomarkers. It enables clearer lesion characterisation and more consistent interpretation while maintaining full clinical control over decision-making and reporting.
Your login details have been sent to the email address linked to your authorised account. Please
follow the instructions included in that email to
access the platform securely.
Thank you.
